Specialty Pharmacy

Top news of the day from across the health care landscape.

Australia on track to achieve World Health Organization targets for eliminating hepatitis C virus over the next 10 to 15 years.

A post hoc analysis of clinical trial data showed oral ozanimod improved cognitive processing speed and reduced annualized relapse rates and MRI lesions in multiple sclerosis.

Dolutegravir plus lamivudine showed non-inferiority to a 3-drug, first-line regimen in treating HIV infection.

Top news of the day from across the health care landscape.

The first study to evaluate population-level roll-out of pre-exposure prophylaxis (PrEP) for HIV in men who have sex with men has demonstrated rapid decline of new HIV infections.

The switchable CAR T system allows for complete control of the cancer-killing cells, which could improve the treatment’s safety.

The FDA has approved dupilumab (Dupixent, Regeneron and Sanofi) in patients with moderate-to-severe asthma aged 12 years and older.

Phase 2 data for evobrutinib shows reduction in lesions and relapse rates in patients with multiple sclerosis.

Nick Calla, RPh, vice president of Industry Relations at Cardinal Health Specialty Solutions, discusses the challenges that consolidation brings to the pharmacy industry and how specialty pharmacies can face those challenges.

An association between hepatitis C virus infection and incident diabetes found among patients who underwent kidney transplantation.

The updated label changes include information regarding use of rituximab as a follow up treatment in adults with 2 rare forms of vasculitis.

One-time, universal screening of hepatitis C virus (HCV) in the general population is cost-effective and could reduce rates of drug-related HCV cases.

Shifting Medicare Part B drugs into Part D may lead to higher costs for Medicare patients with rheumatoid arthritis, according to a new analysis.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

A look at last week's top stories in the world of pharmacy.

Clinical trial demonstrates adoptive T-cell therapy may be successful in treating progressive multifocal leukoencephalopathy.

California’s tobacco control programs have lowered lung cancer deaths 33% faster than the rest of the United States.

Report analyzes HIV-related stigma among health care providers and the potential impact on quality of patient care.

Top news of the day from across the health care landscape.

Broadly neutralizing antibodies have one key advantage over antiretroviral therapy: they have a longer half-life and thus don’t require the daily, lifelong dosing regimen currently required of ART users.

Survey participants reported need for better education on how brain atrophy affects multiple sclerosis progression and cognitive loss.

Olaparib (Lynparza, AstraZeneca and Merck), which is being investigated for the treatment of prostate cancer, receives its fourth orphan drug designation from the FDA.

Top news of the day from across the health care landscape.

Officials with the Centers for Medicare & Medicaid Services this week proposed requiring drug manufacturers to include prices in direct-to-consumer television advertisements for prescription drugs.

Recent preclinical and population evidence shows cannabis modulates inflammatory and fibrotic processes in the liver, which is promising for treating the symptoms of hepatitis C virus.

Talazoparib is indicated for patients with known deleterious or suspected deleterious germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer.